Preclinical toxicology studies with ICRF-159 (NSC-129943)--a new antineoplastic drug.
D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000633:toxicity*; D001831:Body Temperature / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D001853:Bone Marrow / Q000187:drug effects; D003967:Diarrhea / Q000139:chemically induced; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D001068:Feeding and Eating Disorders / Q000139:chemically induced; D005260:Female; D000882:Haplorhini; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D007422:Intestines / Q000187:drug effects; D007970:Leukopenia / Q000139:chemically induced; D008251:Macaca; D008297:Male; D010879:Piperazines / Q000008:administration & dosage / Q000633:toxicity*; D011407:Propane / Q000008:administration & dosage / Q000032:analysis / Q000633:toxicity; D013997:Time Factors; D014839:Vomiting / Q000139:chemically induced
D000970:Antineoplastic Agents; D010879:Piperazines; D011407:Propane